biostudies-literatureUnknown29(1)Gentzler RDMerck &amp; Co., IncMerck Sharp & Dohme LLCCelgene IncMerck & Co., IncMerck Sharp &amp; Dohme LLC<h4>Background</h4>Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC.<h4>Methods</h4>Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) witThe oncologist47-56https://www.ebi.ac.uk/biostudies/studies/S-EPMC10769801biostudies-literaturePhase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.PMC10769801Gentzler RDJalal SIHanna NHHall RDMohindra NAReckamp KLChae YKKoczywas MPatel JDHelenowski IBfalsePhase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.<h4>Background</h4>Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC.<h4>Methods</h4>Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) wit2024-01-01T00:00:00Z2024 Jan2025-04-04T21:54:50.42Z2025-02-19T05:00:43.614ZS-EPMC107698013739061610.1093/oncolo/oyad180